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Abstract
Glial loss in the hippocampus has been suggested as a factor in the pathogenesis of stress-related brain disorders that are
characterized by dysregulated glucocorticoid (GC) secretion. However, little is known about the regulation of astrocytic fate
by GC. Here, we show that astrocytes derived from the rat hippocampus undergo growth inhibition and display moderate
activation of caspase 3 after exposure to GC. Importantly, the latter event, observed both in situ and in primary astrocytic
cultures is not followed by either early- or late-stage apoptosis, as monitored by stage I or stage II DNA fragmentation. Thus,
unlike hippocampal granule neurons, astrocytes are resistant to GC-induced apoptosis; this resistance is due to lower
production of reactive oxygen species (ROS) and a greater buffering capacity against the cytotoxic actions of ROS. We also
show that GC influence hippocampal cell fate by inducing the expression of astrocyte-derived growth factors implicated in
the control of neural precursor cell proliferation. Together, our results suggest that GC instigate a hitherto unknown dialog
between astrocytes and neural progenitors, adding a new facet to understanding how GC influence the cytoarchitecture of
the hippocampus.
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Introduction
Stress and glucocorticoid (GC) hypersecretion during ante-
natal, neonatal, adolescent and adult life are implicated in a
number of brain disorders, including major depression [1,2],
dementia [3], addiction [4] and schizophrenia [5,6]. Neuroim-
aging studies in humans reveal a strong negative correlation
between cortisol levels and hippocampal volume in patients
with major depression [7,8]; importantly, there is a positive
association between cognitive function and cortisol levels [7,9].
Similar structure-behavior relationships have been reported in
the hippocampus, and other brain regions, of laboratory
rodents experiencing high GC levels [10–14]. These volumetric
changes have been ascribed to neuronal atrophy [15] and glial
cell loss [16]. Supporting the latter, postmortem studies report
reduced glial densities and numbers in the prefrontal cortex
(PFC) [17], amygdala [18] and hippocampus [16] of depressed
patients, and Banasr and Duman [19] demonstrated that
chemical ablation of astrocytes in the PFC results in depressive-
like behavior in rats. Moreover, chronic stress has been shown
to induce astrocytic loss in the hippocampus [20], an effect that
can be reversed by drugs with antidepressant actions. While
Banasr et al. [21] found that chronic stress interferes with glial
cell metabolism, through glutamatergic mechanisms, it remains
unclear as to whether GC are causally involved in the loss of
astrocytes after stress. The present study provides unequivocal
evidence that astrocytes respond to GC with growth inhibition
rather than apoptosis. Moreover, this study shows, for the first
time, that GC modify astrocytic production of various growth
factors that ultimately inhibit the proliferation of neural
precursors in the hippocampus.
Results
Astrocytes escape GC-induced apoptosis during
development and adulthood
It has been reported that hippocampal astrocyte numbers are
reduced in GC-related disorders [16,20], suggesting that GC
have a detrimental effect on astrocyte generation or survival. In
the present study we monitored the in situ expression of
phospho-H2A.X, a marker of early apoptosis, in GFAP-positive
cells (astrocytes) within the hippocampal formation of GC-
treated neonatal (1 day old) and adult (3-month old) rats. Results
demonstrate very low co-localization of phospho-H2A.X and
GFAP immunoreactivity in the hippocampus (all subfields) of
neonatal (,5%) and adult (,1%) rats (Fig. 1M-Q), indicating
refractoriness of astrocytes to GC-triggered apoptosis. These
findings contrast strikingly with those previously reported by us
with respect to neural precursor cells [22] and mature neurons
[23–26], and replicated in this study: specifically, we here show
that a significant number of calbindin D28K-positive cells
(neurons) express phospho-H2A.X upon exposure to GC, an
effect that was evident in both, the neonatal and adult
hippocampus (Fig. 1A–L, N, P).
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Figure 1. GC treatment drives neurons but not astrocytes into apoptosis in neonatal and adult rats. A–L, Representative confocal
images showing double staining for calbindin-D28K (A, D, G, J) and phosho-H2A.X (B, E, H, K) in the dentate gyrus of control and GC-treated
neonatal (A–C, G–I) and adult (D–F, J–L) rats. Hoechst 33342 staining was used to identify cell nuclei and to help delineate the SGZ and GCL. Arrows
indicate the representative positive phosphor-H2A.X staining in calbindin-D28K positive neurons. M and O, are representative images showing
double-staining of GFAP and phospho-H2A.X in the stratum radiatum of the hippocampal CA3 and CA1 subfields (CA3-r, CA1-r) in GC-treated
neonatal (M) and adult (O) rats. Arrowheads indicate GFAP-positive astrocytes that were negative for phospho-H2A.X, an early marker of apoptosis.
Arrows indicate the representative phosphor-H2A.X staining in GFAP-negative cells. N and P illustrate the significant increase of apoptosis in
calbindin-positive neurons, but not GFAP-labeled astrocytes, in neonatal (N) and adult (P) rats treated with GC (dexamethasone, 200 mg/kg/d on days
1–3, tapering to 100 mg/kg/d on days 4–7). The counts are from all hippocampal subregions displaying positive signal for calbindin (granule cell layer
of DG) or GFAP (molecular and polymorphic cell layers of DG, and the strata oriens and radiatum of CA1-CA3). Q, Stacking figure showing that GC
treatment does not induce apoptosis in astrocytes in any hippocampal subfield, as indicated by double-staining of GFAP and phopho-H2A.X. The
relative numbers (%) of phospho-H2A.X+/GFAP+ cells relative to total GFAP+ cells in each subfield were calculated; each value was used to create the
stacking figure in which each column represents the % of apoptotic events in astrocytes in each subfield vs. the total number of apoptotic events in
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Phenotypic identity of GC-sensitive hippocampal cells
and mechanisms contributing to GC-insensitivity
The incidence of GC-triggered apoptosis was monitored by
TUNEL and Hoechst 33342 histochemistry in mixed hippocam-
pal cultures transfected with GFP-driven neuron- (Ta1-GFP)
[27,28] and astrocyte- (GFAP-GFP) [29] specific plasmids; the
genetic tagging approach excluded the possibility that astrocytes
undergoing apoptosis might have lost their GFAP antigenicity. As
shown previously [26], maximum apoptotic effects were seen in
the primary hippocampal cultures when DEX was applied at
1025 M, a dose used in all subsequent experiments. This analysis
revealed that neurons (Fig. 2G-I and J), but not astrocytes (Fig. 2D–
F and J), are sensitive to the apoptotic actions of GC. While
confirming results reported in the previous section, this experiment
also revealed that GC treatment increases the expression of active
(cleaved) caspase 3 in astrocytes (Fig. 3A–F); in fact, extended
exposure to GC (up to 144 h) was accompanied by further
increases of activated caspase 3 levels (Fig. 3H) but, nevertheless,
without any significant increase of apoptotic events (data not
shown).
The neuronal effects of GC were prevented by pre-application
of mifepristone (RU38486; 1025 M), a glucocorticoid receptor
(GR) antagonist, indicating their mediation through GR (Fig. 2J).
In astrocytes, which also express GR (Fig. 2A–C), mifepristone
abolished the ability of GC to stimulate active caspase 3 levels
(Fig. 3A–G). Thus, the resilience of astrocytes to the apoptotic
actions of GC most likely reflects the intrinsically different cellular
machineries in astrocytes and neurons.
Further studies were carried out in astrocyte-enriched (.90%,
Fig. 4A) cultures to examine the intrinsic responses of astrocytes to
GC, to specifically exclude potential confounds resulting from
their juxtaposition to neurons in the mixed-cell cultures. Extending
our previous demonstration that GC inhibit proliferation of neural
cells in culture [30], we now show that enriched astrocyte cultures
also exhibit growth inhibition upon exposure to GC and that the
GC effect is abrogated in the presence of the GR antagonist,
mifespristone (Fig. 4B–F). Fluctuations in the levels of cyclins and
cyclin-dependent kinases (CDK), as well as cell cycle inhibitors,
determine the progress of the cell cycle and proliferative capacity
[31]. Here, we show by immunoblotting that GC respectively
down- and upregulate the expression of cyclin D1 and the cell
cycle inhibitor p27 in astrocytes (Fig. 4G and H). These effects
appear to be selective insofar that the levels of other cyclins (e.g.
cyclin E) and CDK6 were not significantly influenced by GC
treatment (Fig. 4G and H).
Astrocytes grown in either serum-free, chemically-defined
medium (Neurobasal A/B27, also used for the mixed-cell cultures)
or standard medium (DMEM), supplemented with charcoal-
stripped (steroid-free) serum, displayed moderate increases in
immunoreactive caspase 3 (active form), but failed to show signs of
apoptosis upon treatment with GC (1029–1025 M), as revealed by
TUNEL and active caspase 3 histochemistry (Fig. 5A–F, J; also see
Fig. 6A). On the other hand, the astrocytic cultures showed
significant levels of caspase 3 activation and apoptosis when
treated with staurosporine (50 nM), a protein kinase inhibitor and
general apoptotic agent (Fig. 5G–I, J). Notably, the dose-response
curves showing astrocytic vs. neuronal apoptotic responses to
staurosporine reveal that astrocytes are less vulnerable to apoptosis
(Fig. 6B).
Apoptotic DNA fragmentation is a two-stage process in which
the DNA is first cleaved into large fragments of 50–300 kb (high
molecular weight [HMW] DNA fragmentation), followed by
subsequent inter-nucleosomal cleavage into low molecular weight
(LMW) fragments [32]. Although LMW fragmentation (identified
by TUNEL, DNA laddering, Hoechst staining) is a widely used
marker of apoptosis, there is strong evidence that apoptosis in
certain cells, and under specific conditions, may be marked by
HMW DNA fragmentation [33]. Accordingly, extracts from GC-
treated astrocytes were subjected to pulse-field gel electrophoresis
and immunoblotting with an antibody against phospho-H2A.X
which marks one of the earliest cellular responses to DNA damage
that subsequently leads to apoptosis [34]. As shown in Figs. 5L and
K, neither HMW DNA fragmentation nor phospho-H2A.X levels
were increased when astrocytes were exposed to GC. In contrast,
both markers were strongly evident in extracts from staurosporine-
treated astrocytes (Fig. 5L and K).
Together, the findings reported thus far in this section suggest
that the differential GC-induced apoptotic response of astrocytes
and neurons reflects divergent post-receptor cellular responses by
the two cell types. At the same time, the results indicate that, as
compared to neurons, astrocytes are endowed with mechanisms
that allow them to more effectively buffer the actions of apoptotic
stimuli.
Since mitochondria play a critical role in the regulation of
apoptosis, including GC-induced apoptosis [35], our initial
investigations into factors and mechanisms that could potentially
render astrocytes resistant to GC-induced apoptosis focused on
mitochondrial function. Previous studies have shown that GC
increase neuronal ROS levels [36,37]. High levels of cellular ROS,
generated by mitochondria as by-products of cellular metabolism,
result in oxidative damage of DNA and other macromolecules and
ultimately lead to cell senescence and death [38]. Here, we asked
whether differences in the rates of ROS generation by neurons
and astrocytes can explain their differential sensitivity to GC-
induced apoptosis. By monitoring ethidium intercalation into
DNA, we found that, as compared to astrocytes, neurons produce
significantly higher levels of ROS under basal conditions, as well
as after GC treatment (Fig. 6C).
The mitochondrial or intrinsic pathway of apoptosis is
rheostatically controlled by pro- and anti-apoptotic proteins [38]
and we previously showed that GC-induced apoptosis in
hippocampal neurons is determined by the relative expression
levels of pro- (Bax) and anti- (BCl-xl, BCl-2) apoptotic molecules
[24]. Results depicted in Fig. 6D and E show that whereas GC
dose-dependently increases the ratio of bax:bcl-2 mRNA levels
(bax:bcl-xl ratios were unchanged) in neurons, astrocytes do not
exhibit major alterations in these profiles; these expression profiles
correlated with the extent of activation of caspase 3 (high in
neurons that ultimately underwent apoptosis, low in astrocytes
which resisted apoptosis; Fig. 6F). These findings suggest that
differences in the ability of astrocytes and neurons to buffer the
cellular actions of GC contribute to their differential vulnerability
to GC-induced apoptosis.
GC regulation of astrocytic cytokines and neuronal cell
turnover
Astroyctes produce a large number of soluble, membrane-
bound proteins and peptides under basal conditions and in
response to neuronal insults. Whereas anisomorphic or reactive
astrocytes in the whole hippocampal formation (100%). o, stratum oriens; m, molecular layer; p, polymorphic cell layer. r, stratum radiatum. * p,0.05
compared to CON. Scale bars: 20 mm.
doi:10.1371/journal.pone.0022419.g001
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astrogliosis leads to exacerbation of the effects of insults, astrocyte
activation (or isomorphic astrogliosis) is thought to play a role in
promoting neuronal survival, repair and proliferation [39]. Since
the expression of several astrocyte-derived cytokines is known to be
regulated by GC [40,41], we here focused on those implicated in
neurogenesis and neuronal survival. Analysis by qPCR revealed
that GC regulate the expression of a number of cytokine genes
whose products could potentially influence the fate of neurons
Figure 2. Astrocytes are spared from GC-triggered apoptosis in primary hippocampal cultures. Hippocampal cultures were genetically
tagged with either Ta-tubulin-GFP or GFAP-GFP plasmids, to identify neurons and astrocytes, respectively. Approximately 50% of astrocytes in typical
cultures displayed GR immunoreactivity (A–C, examples shown by arrowheads). After exposure to GC or vehicle, apoptosis in the different cell
populations was visualized by TUNEL and Hoechst 33342 histochemistry (D–F and G–I). Solid arrowheads exemplify GFP+ cells that entered
apoptosis after GC treatment; open arrowheads indicate non-apoptotic GFP-transfected cells. Numerical data (mean 6 SD) from analysis of TUNEL
staining in either all cells in culture, Ta-tubulin-GFP or GFAP-GFAP sub-populations are depicted in (J). * p,0.05 vs. CON, # p,0.05 vs. DEX. Scale
bars: 50 mm in A–C and 20 mm in D–I.
doi:10.1371/journal.pone.0022419.g002
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through paracrine mechanisms. Specifically, GC significantly
altered the expression of mRNAs encoding death-inducing factors
(fasL, trail, tweak and tnfa, Fig. 7A), neurotrophic factors (bdnf, ngf,
Fig. 7B) and mitogenic factors (bfgf, vegf, Fig. 7C) in astrocyte-
enriched cultures.
Given the complexity of the above reported cytokine expression
patterns, we next investigated whether GC treatment of astrocytes
alters the expression of cytokines implicated in neural cell
turnover. To this end, the effects of conditioned medium (CM)
or conditioned medium from DEX-treated (DCM) astrocytic
cultures (from which small [,MW 3 Kd] molecules were diluted
out serially [final DEX levels: 3.10211 M] or excluded by physical
adsorption) on neurogenesis and apoptosis in primary hippocam-
pal cultures was monitored. As shown in Fig. 8A, neural precursor
cell proliferation was promoted by CM, an effect that was dose-
dependently attenuated when astrocytes were treated with GC
(DCM) (Fig. 8B). Neural precursor cell proliferation was not
observed when cultures were exposed to DEX at a concentration
of 3.10211 M; this, together with the finding that the GR
antagonist RU38486 failed to block the anti-proliferative effects
of DCM, indicates that the effects of DCM did not result from the
effects of residual GC in the CM. Lastly, both CM and DCM
significantly, and to similar extents, attenuated apoptosis (Fig. 8C).
Discussion
The pleiotropic roles of astrocytes have recently been extended
to include the regulation of neurogenesis, migration and synaptic
modulation [42,43], with astrocytic loss and dysfunction being
increasingly implicated in the pathogenesis of psychiatric disorders
such as major depression [17,19–21,44]. However, while some
authors reported a loss of astrocytes [16,20], others reported an
increase in astrocyte densities [45] in the hippocampus of
depressed human subjects and animal models of depression.
Accordingly, the present study involved a detailed analysis of the
direct effects of GC on hippocampal astrocytic fate. In light of
Figure 3. Caspase 3 is activated by GC-treated in astrocytes grown in mixed hippocampal cultures. As compared to vehicle-treated
GFAP-GFP-labeled astrocytes (A–C), those treated with GC (D–F) displayed moderate levels of activated caspase 3. Open arrowheads indicate GFAP-
GFP+/cleaved caspase 32 staining; solid arrowheads indicate GFAP-GFP+/cleaved caspase 3+ cells. The GR antagonist RU38486 significantly
attenuated GC-stimulated activation of caspase 3 (G). Extended exposure of cultures to GC (48–144 h) led to a progressive increase in activated
caspase 3 immunoreactivity in GFAP-GFP tagged astrocytes (H), without causing significant apoptosis monitored by TUNEL and Hoechst staining (not
shown). All numerical data represent mean 6 SD. * p,0.05 vs. CON, # p,0.05 vs. GC. Scale bar: 50 mm.
doi:10.1371/journal.pone.0022419.g003
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previous demonstrations that GC - strongly linked to depression -
induce apoptosis in a subpopulation of hippocampal neurons [22–
24,26,46], we specifically investigated whether GC influence
astrocytic numbers through a similar process.
A first experiment in neonatal and adult rats revealed that,
unlike hippocampal neurons, GFAP-labeled astrocytes do not
succumb to apoptosis after GC administration. This finding was
confirmed in more detailed analyses performed on primary
hippocampal cultures (containing neurons and glia) as well as
cultures enriched in hippocampus-derived astrocytes. Since the
apoptotic process, from cell rounding and membrane blebbing
through to lysis, can last between 12 and 24 h [47], and because
individual cells may be asynchronous in their sensitivity, we here
treated cultures with a synthetic GC (dexamethasone) for 48 h to
capture all potential apoptotic events. Subsequently, early (stage I)
or late (stage II) stages of DNA fragmentation were monitored,
using immunoblotting with anti-phospho-H2A.X and pulsed-field
gel electrophoresis (stage I) or TUNEL and Hoechst staining (stage
II), respectively. Neither stage of DNA fragmentation was
observed in astrocytes exposed to GC, indicating that astrocytes
may be resistant to GC-induced apoptosis.
First attempts to identify the mechanisms that may contribute to
the resistance of astrocytes to the apoptotic actions of GC revealed
that, as compared to neurons, astrocytes have lower levels of
reactive oxygen species (ROS) under resting conditions and
generate lower ROS levels when exposed to GC. Thus, astrocytes
are less likely to suffer from ROS-induced disruption of the
mitochondrial membrane permeability, a major trigger of
apoptosis [48]. Mitochondrial membrane permeability and thus,
cell survival, is rheostatically regulated by pro- and anti-apoptotic
members of the BCl2 family [24,49]. Our finding that astrocytes
can maintain a higher ratio of anti-apoptotic (BCl-2 and BCl-xL)
to pro-apoptotic (Bax) protein levels after exposure to GC indicates
that astrocytic refractoriness to GC-induced apoptosis may
critically depend on this attribute.
Astrocytes exposed to GC display moderate increases in the levels
of activated caspase 3, the so-called ‘executioner caspase’ even
though they do not respond to this particular stimulus with signs of
apoptosis. Our finding that staurosporine can trigger apoptosis in
astrocytes not only verifies an intact apoptotic machinery but also
indicates that, as compared to staurosporine, GC cannot elicit a
sufficiently strong activated caspase 3 response. Previous studies
Figure 4. Anti-proliferative actions of GC in astrocytes are GR-dependent. A, Representative immunostaining of GFAP in the enriched
astrocytic culture. B–E, are representative images showing BrdU incorporation in control (B, C) and GC-treated (dexamethasone, at 1025 M for 48 h
in medium with charcoal-stripped serum) astrocytes (D, E). Hoechst 33342 counterstaining demonstrates comparable cell densities. BrdU (20 mM)
was added to cultures 12 h before fixation. F, shows that the anti-proliferative actions of GC are counteracted by addition of the GR antagonist,
RU38486 (1025 M). G, Representative Western blots showing GC (dexamethasone; 1025 M in medium supplemented with charcoal-stripped serum;
48 h) regulation of various key regulators of the cell cycle in cultured astrocytes; the semi-quantitative (n = 4) data from these immunoblotting
experiments are shown in H. Note that while GC treatment downregulates cyclin D1 protein expression, the treatment results in a concomitant
increase in the levels of the cell cycle inhibitor, p27. Cyclin E and CDK6 expression levels are not changed after exposing astrocytes to GC. Numerical
data represent mean 6 SD. * p,0.05 vs. CON, # p,0.05 vs. GC. Scale bar: 50 mm.
doi:10.1371/journal.pone.0022419.g004
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have ascribed non-apoptotic functions to caspases (reviewed by
Fernando and Megeney) [50]. For example, studies in cells of
both, neuroepithelial [51–54] and mesodermal [55–57] origin
suggest that activated caspase 3 plays a crucial role in cell
differentiation. This notion is further supported by the recent
finding that astroglial caspase 3 activation is not accompanied
with cell death, but rather leads to cytoskeleton remodeling [58].
Our finding that GC cause astrocytic growth inhibition by
inducing exit from the cell cycle (reduction of cyclin D1 and
concomitant increase of p27) also supports the view that GC may
contribute to the functional remodeling of astrocytes. Interest-
ingly, in contrast to their targeting highly selective neuronal
populations for apoptosis [59], GC have been reported to induce
cell cycle arrest in a variety of neural cells, including neural
precursors [60], microglia [61] and a neuroblastoma cell line
[30]. To our knowledge, this is the first study to show that GC
can also inhibit the proliferation of astrocytes while inducing their
functional differentiation (see below). It therefore provides a new
perspective on how elevated GC secretion may contribute to
psychiatric illness.
Figure 5. Enriched astrocytic cultures also respond to GC with moderate activation of caspase 3, but fail to show signs of early- or
late-stage apoptosis. After re-plating, enriched astrocytic cultures were treated with GC (48 h) in medium containing either charcoal-stripped
serum (data not shown) or B27 supplement (representative images in A–L). Enriched astrocytes responded to GC treatment DEX with moderately
increased immunostaining for activated caspase 3; these cells did not enter late-stage (stage II) apoptosis, as shown by TUNEL (A–F). In contrast,
staurosporine (STA) induced a marked activation of caspase 3 and apoptosis (G–I). The immunocytochemical results shown for activated caspase 3 in
A–I were confirmed by immunoblotting (J). Staurosporine, but not GC, treatment of enriched astrocytic cultures significantly increased levels of
immunoreactive phospho-H2A.X, a marker of early apoptosis, as shown by immunoblotting studies (K). Similarly, astrocytes exposed to STA, but not
GC, displayed high molecular weight (HMW) DNA fragments, when lysates where subjected to pulse-field gel electrophoresis (PFGE) (L); all lanes were
loaded with DNA from the same number of astrocytes, and arrow indicates 50 kb HMW DNA fragments. Scale bars: 50 mm.
doi:10.1371/journal.pone.0022419.g005
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PLoS ONE | www.plosone.org 7 July 2011 | Volume 6 | Issue 7 | e22419
Previous findings reported that GC alter the expression of
astrocytic genes such as glutamine synthetase [62], GLT-1 [63]
and interleukin-1 receptor [64]. These observations, together with
results from the present study, show that the astrocytic
transcriptome is influenced by GC. Interestingly and notwith-
standing their potential roles in astrocytic insensitivity to GC-
induced apoptosis, GC modulate the expression of a number of
genes implicated in the regulation of neurogenesis in the
hippocampus. However, the mRNA expression profiles of GC-
treated astrocytes are difficult to interpret at present (e.g. the
observed patterns of bfgf and vegf expression appear to be counter-
intuitive). Importantly, this study shows that GC-induced changes
in astrocytic function have a substantial influence over neurogen-
esis; the latter most likely involve the recruitment of, and cross-talk
Figure 6. Insights into potential mechanisms underlying astrocytic resistance to GC-induced apoptosis. Astrocytes show less
susceptibility to GC- (A) and staurosporine (STA)-induced (B) apoptosis, as compared to neuronal cells. Both neurons and astrocytes respond to GC
treatment with a significant increase of ROS (measured by fluorescent DHE nuclear translocation) (C); note that, as compared to neurons, astrocytes
generate markedly lower levels of ROS under basal conditions and after GC treatment. The ratios of expression of mRNAs for pro- vs. anti-apoptotic
members of the Bcl2 family (bax vs. bcl-XL and bcl-2) are different in neurons and astrocytes (D and E); mRNA levels were determined by qPCR.
Neurons and astrocytes also respond differentially to GC treatment in terms of their activated caspase 3 responses (measured by immunoblotting)
(F), with astrocytes showing smaller increases in levels of activated caspase 3. Numerical data are shown as mean 6 SD. * p,0.05 vs. neuron CON;
# p,0.05 vs. astrocyte CON; + p,0.05 GC-treated neurons vs. GC-treated astrocytes. Scale bars: 25 mm.
doi:10.1371/journal.pone.0022419.g006
Astrocytic Response to Glucocorticoids
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with, multiple effectors that play decisive roles in the pathways that
regulate neural death and proliferation. To our knowledge, this
represents the first report in which astrocytes are implicated as
paracrine mediators of the negative effects of stress and GC on the
proliferation of hippocampal neurons. To date, research on the
regulation of neurogenesis and neuronal cell numbers by stress,
GC and antidepressants [65] has been largely focused on the
intrinsic mechanisms that control the birth and differentiation of
neural precursors [60]. Our finding that neurogenesis is subject to
extrinsic controls through GC-induced changes in astrocytic
function adds a new dimension to present views of the
pathophysiology of depression and other mental disorders in
which dysregulation of hippocampal cytoarchitecture is causally
implicated.
In summary, our studies show that hippocampal astrocytes do
not enter the apoptotic pathway upon treatment with GC;
accordingly, we conclude that the reduced number of astrocytes
observed after exposure of animals to stress cannot be explained by
GC-induced apoptosis. Our results indicate that, as compared to
neurons, astrocytes are equipped with ROS load-reducing
mechanisms that promote their survival. At the same time, GC
appear to activate cellular pathways that result in an attenuation of
neural proliferation. Together, these observations suggest that GC
can dictate hippocampal architecture and ultimately function by
initiating a hitherto undisclosed dialog between astrocytes and
neurons.
Materials and Methods
Drugs and plasmids
The glucocorticoid receptor (GR) agonist dexamethasone
(DEX), obtained from Merck (Darmstadt, Germany) in aqueous
solution, was added to cultures for 48 h (24 h after transfection).
The GR antagonist, mifepristone (RU38486; provided by the
National Hormone and Pituitary Program, Torrance, CA) was
added (10 mM) 1 h before the application of DEX. Cells
undergoing mitosis were labeled by addition of 5-bromo-29-
deoxyuridine (BrdU; 20 mM; Sigma, St. Louis, MO) to cultures for
4 h. Staurosporine (Sigma) was used at 50 nM to induce apoptosis
in astrocytes. The plasmids pBSII SK-Ta1-GFP (kind gift of Dr.
Freda Miller) [27,28] and pGFAP-GFP (kind gift of Dr. Helmut
Kettenmann) [29] were used to label neurons and astrocytes,
respectively.
Primary hippocampal and enriched astrocyte cultures
Unless specified, all cell culture materials were purchased from
Invitrogen (Eggenstein, Germany). Hippocampal neuronal cul-
tures were prepared from Wistar rats aged 4 days (P4; Charles
River, Sulzfeld, Germany), following a previously published
protocol [66]. Transfections were carried out after 5–6 days in
vitro (DIV), using Lipofectamine 2000 (Invitrogen) [66]. Trans-
fection efficiency, judged by control transfection with pEGFP, was
,10%.
Enriched astrocytic cultures were obtained from hippocampi
from P4 rats [66], plated at a density of 130 cells/mm2 in DMEM
containing 10% fetal bovine serum (FBS) and 1% kanamycin.
After 12 days in vitro (DIV), cultures were shaken (260 rpm, 20 h)
and washed with cold PBS. After discarding the supernatant, the
residual cells were trypsinized and replated. Experiments were
performed on astrocytes in their third passage in vitro and,
depending on the specific treatments, were transferred into either
DMEM/10% charcoal-stripped FBS (to exclude confounding by
steroids in serum), DMEM/N2 Supplement or Neurobasal/B27
medium (to allow comparisons between glia and neurons).
Conditioned medium
After washing with PBS, astrocytes were maintained for 48 h in
Neurobasal A/B27 medium 6 DEX. The growing medium
Figure 7. Temporal mRNA expression profiles of growth- and
survival-regulating peptides in GC-treated astrocytes. A,
molecules implicated in the extrinsic death pathway; FasL mRNA was
transiently increased, TRAIL and TWEAK mRNAs showed transient
reductions and TNFa mRNA showed a sustained reduction after
application of GC. B, expression patterns of the mRNAs encoding the
neurotrophic factors BDNF (transient upregulation) and NGF (sustained
downregulation) after GC treatment. C, levels of mRNA encoding for
the mitogenic factors bFGF (increased) and VEGF (decreased) following
exposure of astrocytes to GC. In all analyses, gapdh and actin served as
housing-keeping gene controls. Values shown derive from 3 indepen-
dent experiments (mean 6 SD).
doi:10.1371/journal.pone.0022419.g007
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(hereinafter referred to as conditioned medium, CM) was then
harvested and centrifuged (300 rpm, 3 min, to remove residual
cellular material); supernatants were then either concentrated or
extracted to exclude DEX. For concentration, supernatants were
run through Vivaspin columns (Vivaspin20, Sartorius, Aubagne,
France) to concentrate peptides with an Mr .3 kD; smaller
molecules, including DEX at an initial concentration of 1025 M,
were washed out serial dilution-concentration steps to reach a
estimated final concentration of DEX that was ,3.10211 M. To
extract DEX, supernatants were run through Speedisk H2O-
Phobic DVB polymer columns (JT Baker, Phillipsburg, NJ).
Complete removal of DEX from CM and DCM was evidenced by
the disappearance of the phobic indicator, phenol red.
Quantitative PCR
Total RNA was isolated (RNAeasy kit; Qiagen, Hilden,
Germany) and reverse transcribed with Superscript II RNA H-
reverse transcriptase (Invitrogen) and custom-synthesized Oligo-
dT12-18 primers (MWG Biotech, Ebersberg, Germany). Quan-
titative PCR (qPCR) was performed with a LightCycler (Roche,
Mannheim, Germany) in 10 ml mixtures containing 2 ml of 5X
master mix (FastStart DNA SYBR green I; Roche), 5 ml of water,
0.5 ml of each primer and 2 ml of extracted DNA. The reaction
was performed with preliminary denaturation for 10 min at 95uC
(slope, 20uC/s), followed by 40 cycles of denaturation at 94uC
(5 s), annealing (5 s) at 65uC and extension at 72uC (10 s). Relative
mRNA expression ratios (housekeeping genes: actin and gapdh)
were subsequently calculated. The following primers were used:
bax (174 bp) fwd: CTGCAGAGGATGATTGCTGA; rev: GAT-
CAGCTCGGGCACTTTAG
bcl-2 (251 bp) fwd: CGGTGGTGGAGGAACTCTTC; rev: CAGC-
CAGGAGAAATCAAACAGA
bcl-2 (251 bp) fwd: TGACCACCTAGAGCCTTGGAT; rev: CAG-
GAACCAGCGGTTGAAA
fas-l (255 bp) fwd: AAGGAGTGTGGCCCACTTAAC; rev:
CTTCTCCTCCATTAGCACCAG
tnfa (221 bp) fwd: CCCAGACCCTCACACTCAGATCAT; rev:
GCAGCCTTGTCCCTTGAAGAGAA
trail (167 bp) fwd: GCTTGCAGGTCAAGAGGCAAC; rev:
TCTCCGAGTGATCCCGGTAATG
tweak (154 bp) fwd: CTGTCAGGTGCACTTTGATGAG; rev:
AGCAAGTCCAGCTTCAGGTAGA
bdnf (111 bp) fwd: AAGGCTGCAGGGGCATAGAC; rev:
TGAACCGCCAGCCAATTCTC
Figure 8. Conditioned medium from GC-treated astrocytes influences neurogenesis in hippocampal cultures. A, Treatment of primary
hippocampal cultures with DCM (conditioned medium harvested from GC-treated astrocytes) attenuated the mitotic effects of CM (conditioned
medium from normal astrocytes), measured by BrdU incorporation and Ki67 immunostaining. Conditioned media were prepared by either serial
concentration (to reduce dexamethasone concentrations to ,3.10211 M; CM and DCM) or physical absorption of dexamethasone (CM-hydro and
DCM-hydro). The effects of DCM could not be antagonized with GR antagonist, RU38486 (1028 M). Neither dexamethasone (3.10211 M) nor RU38486
(1028 M) exerted significant effects on neural proliferation, and DCM-hydro attenuated the mitotic effects of CM-hydro to similar extents. B, CM
caused a dose-dependent increase in neural proliferation, whereas DCM reduced the stimulatory effects of CM. C, Apoptosis in primary hippocampal
cells in culture were reduced by CM and DCM to similar extents. Numerical data represent mean6 SD. * p,0.05 vs. CON, + p,0.05 vs. corresponding
CM group.
doi:10.1371/journal.pone.0022419.g008
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ngf (142 bp) fwd: CCAAGCACTGGAACTCATACTGC; rev:
CTGCTGAGCACACACACGCAG
bfgf (216 bp) fwd: GACCCACACGTCAAACTACA; rev:
TTTCAGTGCCACATACCAAC
vegf (196 bp) fwd: CCTGGTGGACATCTTCCAGGAGTACC; rev:
GAAGCTCATCTCTCCTATGTGCTGGC
gapdh (116 bp) fwd: TGGAGAAACCTGCCAAGTATG; rev:
GTTGAAGTCGCAGGAGACAAC
actin (76 bp) fwd: GGGAAATCGTGCGTGACATT; rev:
GCGGCAGTGGCCATCTC
Pulse-field gel electrophoresis
Fragmentation of high molecular weight (HMW) DNA was
assayed by pulse-field gel electrophoresis (CHEF-DR II; Biorad,
Hercules, CA). Approximately 5.106 astrocytes per condition were
suspended in 40 ml of PBS, mixed with an equal volume of warm
1% Seakem gold agarose (SKG; Bio Whittaker Molecular
Applications, Rockland, MD) in 0.5X TBE buffer (45 mM Tris,
45 mM boric acid, 1 mM EDTA, pH 8.3), and transferred to
block molds (Biorad). Agarose blocks were incubated at 50uC in
1 ml of NDS buffer (1% laurylsarkosyl, 10 mM Tris, 0.5 M
EDTA, pH 9.5) containing 200 mg/ml proteinase K, and then in
NDS buffer containing 10 mg/ml RNase; each incubation lasted
24 h. The blocks were inserted into wells of a 1% SKG gel in 0.5X
TBE, and electrophoresed at 6V/cm for 14 h at 14uC with a
switch time of 5–50 s.
Reactive oxygen species (ROS) generation. Generation of
ROS was assayed by allowing dihydroethidium (DHE; 5 mM) to
react (30 min; 37uC) with cellular superoxide ions to yield a red
fluorescent ethidium product. After washing and fixation in 4%
PFA, ethidium accumulation in the cell nucleus was monitored by
fluorescence microscopy (excitation, 520 nm; emission, 590 nm).
Observations were made in hippocampal (mixed cell types and
astrocyte-enriched) cultures under basal conditions and after
exposure to DEX.
Immunochemistry. Cells were fixed in 4%
paraformaldehyde, permeabilized in Triton-X100/PBS (0.3%)
and blocked in 5% donkey serum/0.3% Triton (30 min) before
incubation (4uC, overnight) with primary antibodies: anti-BrdU
(1:200; DAKO, Hamburg, Germany), anti-GFAP (1:2000;
DAKO), anti-GR (1:300; Santa Cruz) and anti-active caspase 3
(1:200; Cell Signaling/NEB, Frankfurt, Germany). For BrdU
staining, cells were permeabilized, treated with 2N HCl (30 min)
and incubated with anti-BrdU. After washing in PBS, cells were
incubated (1 h, RT) with appropriate secondary AlexaFluor 488/
594 conjugates (1:500; Invitrogen). Nuclei were stained with
Hoechst 33342 (1 mg/ml in PBS, 10 min). TUNEL histochemistry
was performed as previously described [26], using FITC- or Texas
Red-conjugated avidin (Vector Labs; Burlingame, CA) for signal
visualization. Double staining of H2A.X and calbindin D28K or
GFAP was performed using the following antisera (48 h
incubations at 4uC): mouse anti-phospho-H2A.X (Millipore,
Schwalbach, Germany; 1:500) and rabbit anti-calbindin D28K
(Millipore; 1:500) or rabbit-anti-GFAP (DAKO). Appropriate
Alexa conjugates were used to visualize immunoreactive signals.
Specimens were examined on an Olympus BX-60 microscope,
video-lined to a computer equipped with image-processing
software (ImagePro, Media Cybernetics, Bethesda, MD). Cell
counts were performed on 10 individual microscopic fields
(0.072 mm2), randomly chosen across two diameters of each
coverslip (400X magnification). An average of 1,000 cells or 100
transfected cells were sampled on each coverslip; results shown
represent values from 6–9 coverslips/treatment.
Apoptosis in rat hippocampus. Experiments were
conducted in accordance with local regulations (Regierung von
Oberbayern License 2531-22-07) and European Union Directive
(EU8869/10). Male Wistar rats born in-house to mothers from
Charles River (Sulzfeld, Germany) were housed under standard
laboratory conditions (12 hours light cycle; food and water
available ad libitum). Rats (1 day or 3 months old) received daily
s.c. injections of either vehicle (saline; n = 5) or a tapering dose of
DEX (days 1–3: 200 mg/kg/d; days 4–7: 100 mg/kg/d; n = 6) and
were sacrificed 24 h after the last injection. Brains were snap-
frozen in a bath of isopentane and serial cryo-sections (20 mm each
at intervals of 160 mm) were thaw-mounted onto gelatin-subbed
glass slides, air-dried, and stored at 280uC until processing for
immunohistochemistry. Incidence of apoptosis in calbindin D-
positive neurons and GFAP-positive astrocytes was detected by
phospho-H2A.X-staining. Sections were examined by confocal
laser-scanning microscopy (Olympus IX81; 60X water-immersion
lens) and results shown derive from evaluation of cells randomly
selected within defined hippocampal subregions (100 neurons, 100
astrocytes; 4 sections per animal).
Lysate preparation and western blotting. Cells were lysed
in 100 mM Tris-HCl, 250 mM NaCl, 1 mM EDTA, 5 mM
MgCl2, 1% NP-40, a cocktail of protease inhibitors (Complete
Protease Inhibitors; Roche, Mannheim, Germany) and
phosphatase inhibitors (Sigma) for 30 min and cleared by
centrifugation at 13,000 g for 20 min. After determination of
protein concentration (Lowry method), samples were separated by
SDS-PAGE on 10%-15% polyacrylamide gels, and transferred to
nitrocellulose membranes. Membranes were blocked in PBS
containing 5% non-fat milk and 0.2% Tween-20, and incubated
overnight with antisera against phospho-H2A.X (1:1000), active
caspase 3 (1:200), cyclinD1 (1:300; Santa Cruz), cyclin E (1:500;
Santa Cruz), CDK6 (1:500; Santa Cruz) or p27 (1:500; Santa
Cruz). Specific protein bands were revealed by enhanced
chemiluminescence (GE Life Sciences, Freiburg, Germany), after
incubation with appropriate horseradish peroxidase-IgG
conjugates (GE Life Sciences).
Statistics. All numerical data (mean 6 SEM) were subjected
to ANOVA and appropriate post-hoc analysis, using SPSS
software (v.10.0; SPSS Inc, Chicago, IL). The level of
significance was preset at p,0.05.
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